India’s CRO industry is playing catch-up to the generic and manufacturing sectors, according to the departing CEO of one of the largest players, Syngene.
The Pfizer-Allergan $160bn merger will create the world’s largest pharma company but potentially not for long, as the two CEOs discuss breaking the entity up in 2018.
Higher quality data could convince pharma firms to pay to trial generic drugs for new indications say researchers calling for diclofenac to be studied as a cancer treatment.
As the industry faces new challenges in 2016, the pharmaceutical industry is expected to be the second busiest sector for consolidation with large cash reserves driving deals, according to experts.
UK pharma manufacturing output increased last year according to EEF, which says lower costs and a legacy of R&D investment will drive further growth in 2016.
Newly private WuXi AppTec has announced plans to invest $120m in a biopharmaceutical development laboratory and clinical-scale manufacturing facility in Shanghai, China.
A chemotherapy drug marketed by Eagle Pharmaceuticals has become the first product approved for commercial manufacture from AMRI’s once troubled Burlington facility.
Fresenius Kabi has moved into the prefilled syringe space by acquiring Becton, Dickinson and Company’s injectables business and US manufacturing plant.
Charles River is set to acquire WIL Research for approximately $585 million in cash, further enhancing the company’s capabilities to include contract development and manufacturing (CDMO).
Despite Sanofi’s “conflicted” management and subsequent abandonment of Afrezza, the market opportunity for inhaled insulin is still huge, according to Dance Biopharm's CEO.
Medidata expects to become a strategic partner to even more pharma firms as Boehringer Ingelheim becomes the latest to transition to its cloud technology platform.
In 2016 clinical trial and real-world data will become increasingly important in the decision to prescribe medicine, Parexel President and COO Mark Goldberg told Outsourcing-Pharma.com.
The global clinical trial management system (CTMS) market is expected to grow 14% over a five-year period hitting an almost $2bn valuation by 2019, according to a new market report.
Dr Reddy’s has changed the colour of its Nexium generic capsules from purple to blue in a bid to resume US sales, as litigation with AstraZeneca continues.
Sanofi has abandoned Afrezza less than a year after its launch, but the future of the inhaled insulin product is secure according to developer MannKind.
Having a proactive approach to delivery technologies will give pharma firms a competitive edge against biosimilars and biobetters, according to device maker Bespak.
MIT engineers have designed a new hydrogel material that can incorporate temperature sensors, LED lights, and other electronics – in addition to drug-delivering reservoirs.
Many generic drugs are not truly bioequivalent to the original medicines they copy and switching to them can lead to worse patient outcomes, according to US researchers.
Software firm LZ Lifescience says small drugmakers could increase their productivity by over 25% by accessing Manufacturing Execution Systems (MESs) traditionally restricted to Big Pharma firms
The end of the year is always a time for reflection, and as Andrew Schafer, ISR President told us, “2015 was a very interesting year for pharmaceutical service providers.”
The US FDA has warned Sun Pharmaceutical Industries about its facility in Halol, India just months after it withdrew approval for an epilepsy drug made at the site.
